CN102366640A - Zeolite tourniquet bandage - Google Patents
Zeolite tourniquet bandage Download PDFInfo
- Publication number
- CN102366640A CN102366640A CN2011103116523A CN201110311652A CN102366640A CN 102366640 A CN102366640 A CN 102366640A CN 2011103116523 A CN2011103116523 A CN 2011103116523A CN 201110311652 A CN201110311652 A CN 201110311652A CN 102366640 A CN102366640 A CN 102366640A
- Authority
- CN
- China
- Prior art keywords
- zeolite
- hemostatic
- binder
- stanching
- tourniquet bandage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 title claims abstract description 72
- 239000010457 zeolite Substances 0.000 title claims abstract description 71
- 229910021536 Zeolite Inorganic materials 0.000 title claims abstract description 70
- 239000000843 powder Substances 0.000 claims abstract description 34
- 239000011230 binding agent Substances 0.000 claims abstract description 29
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 14
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 claims abstract description 12
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims abstract description 10
- 150000003863 ammonium salts Chemical class 0.000 claims abstract description 7
- 239000011780 sodium chloride Substances 0.000 claims abstract description 7
- 239000004202 carbamide Substances 0.000 claims abstract description 6
- 235000010333 potassium nitrate Nutrition 0.000 claims abstract description 6
- 239000004323 potassium nitrate Substances 0.000 claims abstract description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 claims abstract description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims abstract description 5
- 239000011248 coating agent Substances 0.000 claims abstract description 3
- 238000000576 coating method Methods 0.000 claims abstract description 3
- 230000002439 hemostatic effect Effects 0.000 claims description 50
- 239000000203 mixture Substances 0.000 claims description 29
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical group [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 5
- 239000001110 calcium chloride Substances 0.000 claims description 5
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 5
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 5
- 235000013877 carbamide Nutrition 0.000 claims description 5
- 239000004115 Sodium Silicate Substances 0.000 claims description 4
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 claims description 4
- 229910052911 sodium silicate Inorganic materials 0.000 claims description 4
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 claims description 3
- 239000005995 Aluminium silicate Substances 0.000 claims description 3
- 235000012211 aluminium silicate Nutrition 0.000 claims description 3
- 235000019270 ammonium chloride Nutrition 0.000 claims description 3
- 239000004927 clay Substances 0.000 claims description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000007613 environmental effect Effects 0.000 abstract description 2
- 238000007789 sealing Methods 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 description 27
- 208000032843 Hemorrhage Diseases 0.000 description 17
- 239000000463 material Substances 0.000 description 13
- 230000023597 hemostasis Effects 0.000 description 11
- 230000000025 haemostatic effect Effects 0.000 description 8
- 230000000740 bleeding effect Effects 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 208000014674 injury Diseases 0.000 description 5
- 230000006378 damage Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 229940030225 antihemorrhagics Drugs 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 239000002808 molecular sieve Substances 0.000 description 3
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 3
- 239000009306 yunnan baiyao Substances 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical group [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- CQBLUJRVOKGWCF-UHFFFAOYSA-N [O].[AlH3] Chemical compound [O].[AlH3] CQBLUJRVOKGWCF-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 238000001354 calcination Methods 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- -1 silicon (aluminum) oxygen Chemical compound 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229910018516 Al—O Inorganic materials 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 229910018557 Si O Inorganic materials 0.000 description 1
- 229910004283 SiO 4 Inorganic materials 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- KMWBBMXGHHLDKL-UHFFFAOYSA-N [AlH3].[Si] Chemical group [AlH3].[Si] KMWBBMXGHHLDKL-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000001266 bandaging Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000009432 framing Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000005504 petroleum refining Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- LIVNPJMFVYWSIS-UHFFFAOYSA-N silicon monoxide Inorganic materials [Si-]#[O+] LIVNPJMFVYWSIS-UHFFFAOYSA-N 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 239000003634 thrombocyte concentrate Substances 0.000 description 1
- 230000001026 thromboplastic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a zeolite tourniquet bandage, which belongs to the technical field of medical supplies. The zeolite tourniquet bandage comprises medical gauze, which adsorbs stanching components, and the stanching components comprise, by weight, 50% to 95% of zeolite powder, 3% to 30% of one or more selected form the group consisting of sodium chloride, potassium nitrate, ammonium salt, urea and sodium bicarbonate and 2% to 20% of a binder. According to the invention, the stanching components and the medical gauze are formed once for all and are subjected to sterile sealing, which enables such problems of conventional stanching products as a high price, nonuniform coating, proneness to external environmental affection, troublesome utilization and the like to be overcome. The zeolite tourniquet bandage provided in the invention has the following advantages: it is convenient to carry, preserve and utilize the zeolite tourniquet bandage; cost is low; a production process is simple; a good stanching effect, low heat release and no side effects are obtained; the zeolite tourniquet bandage can be widely used as a first-aid kit in laboratories, medical stations, household first aids and field works.
Description
Technical field
The present invention relates to binder, be specifically related to a kind of Zeolite hemostatic binder.
Background technology
Human body can transport blood coagulation substance---the platelet of self from the trend wound after receiving wound, solidify to form the hemostasis piece, reaches the hemostatic purpose.If can not stop blooding naturally but wound is excessive.In operation, can use the machinery hemostasis; Also can smear thrombin in the wound and help hemostasis; But most of hemorrhage occasions that occur in beyond the operating room; All because of the careless massive hemorrhage that causes, therefore how quick-acting haemostatic powder becomes vital important measures like traffic accident, natural disaster, burst accident, outdoor activities, industrial injury, war etc.In Iraq's campaign, have 50% personnel of falling in battle to be because before sending to the medical center because of due to the severe loss of blood.U.S. every year is because of about 50,000 people of severe loss of blood death toll, and China is populous, and safety measure, medical condition, means of transportation etc. are perfect inadequately; The death toll of losing blood so is certainly far above this number; These the wounded first aid timely and effectively hemostasis is raced against time, thereby can be saved its life.Existing hemostatic material has hemostatic gauze, stanch fibre, tourniquet; Limitation is all arranged in use: though loss has tangible haemostatic effect to extremity like hemostasis required time length, bundle tourniquet; But owing to blocked the blood flow at the upper reaches, injury; Can cause remote organization's ischemia and necrosis, making must amputation.
Once reported multiple hemorrhage abroad, it is hemorrhage to be used to control trunk, mainly contain fibrin sealant (FD dressing), the dressing of poly N-acetyl glucosamine etc., but these hemorrhage prices is higher, or character is unstable, thereby has limited its application.The U.S. has researched and developed a kind of novel styptic powder Quikclot at the beginning of 2002, be a kind of particulate powder, and outer appearnce adopts aseptic waterproof vacuum-packed like desiccant, tears packing during use, and particulate powder directly is poured on the wound, gets final product quick-acting haemostatic powder.Quikclot be a kind of from zeolite or with natural or artificial silicate like the zeolites the molecular sieve material extracted; Significantly improved the wounded's survival rate on the battlefield after the use; But find after a large amount of the use that a safety problem is that the QuikClot suction can discharge great amount of heat afterwards; Sometimes even can cause second degree burn, but when injury was enough to life-threatening safety, this hemorrhage had also played crucial effects.
Zeolite is a kind of aluminosilicate crystalline material, have the ability of pore passage structure with the screening molecule of rule, and its specific surface area and surface acidity is adjustable, are widely used as adsorbent, catalyst, separating medium and various functional material.Along with the deep development of correlational study, the range of application of zeolitic material develops to environmental conservation box life science from petroleum refining, petrochemical industry and fine chemistry industry.Hemorrhage for trunk, to compare with the dressing Pressur hemostatic, Zeolite hemostatic rapidly and stable and the zeolite convenient in application, is very suitable for emergency care of trauma.Zeolite is owing to wide material sources, and is cheap, characteristics such as good stability, and it is expected to become high-performance hemostatic material of new generation.Zeolite hemostatic it is generally acknowledged that it is through the moisture in the absorbing blood, thereby has improved the concentration of blood coagulation substrate, and the quickening blood coagulation is reacted and stopped blooding.But because zeolite suction meeting heat release, the highest exothermic temperature can reach 100
oC can cause obvious heat loss to skin when therefore being used for wound, and in the war in Iraq, the wounded of U.S. army use zeolite powder to be sprinkling upon the wound, and temperature raises and causes the limbs burn.
Application number is that 200710017566.5 Chinese patent discloses a kind of externally-applied zeolite hemostat and preparation technology thereof; It is to be the 5A Zeolite modifying of 0.50mm～0.75mm with particle diameter; After loading an amount of silver-colored zinc metal ion; Drying and dehydrating adds an amount of alginate material powder mixing again and gets final product in the modified zeolite granule.The present invention significantly reduced the heat that its suction exothermic reaction produces afterwards through zeolite silver loaded zinc metal ion, body is not had hot injury's effect, but silver was heavy metal; Cost an arm and a leg,, can't prove at present whether it can residue in wound surface and harmful though it can antibacterial; In addition; Need during use hemorrhage is coated on the wound, exist to apply still easy infection of inhomogeneous, exposed wound, receive problems such as the influence of external environment is bigger.
Application number is that 200710017566.5 Chinese patent discloses a kind of Zeolite hemostatic dressings; The Zeolite hemostatic dressings that Zeolite hemostatic dressings of the present invention is prepared by 4A zeolite, binding agent, lignin and optional molecular sieve activation powder; The present invention also provides a kind of first-aid kit, can place bleeding-stopping dressing and binder or gauze in the first-aid kit, fast, aseptic, the no thermal source of Zeolite hemostatic dressings anthemorrhagic speed of the present invention; But as reuse gauze or bandaging behind the use bleeding-stopping dressing; Required time is longer, may delay treatment, therefore there is problems such as using inconvenience.
Summary of the invention
The object of the present invention is to provide a kind of production technology simple; Cost is low, and is easy to use, and Zeolite hemostatic binder fast and without any side effects stops blooding; Solved existing Zeolite hemostatic valuable product, apply inhomogeneous, be subject to the external environment influence, use problems such as trouble.
Above-mentioned technical purpose of the present invention is achieved through following technical scheme: a kind of Zeolite hemostatic binder; Comprise hospital gauze; It is characterized in that: on hospital gauze, be adsorbed with hemostatic compositions, said hemostatic compositions comprise by weight percentage in 50% ~ 95% zeolite powder, 3% ~ 30% sodium chloride, potassium nitrate, ammonium salt, carbamide, the sodium bicarbonate one or more, 2% ~ 20% binding agent.
Zeolite powder is a kind of nontoxic, odorless, tasteless and mobile white powder preferably, has stronger calcium ion exchange capacity, and chemical composition generally is expressed as M
2O
nAl
2O
3XSiO
2YH
2O.Zeolite be a kind of be the molecular sieve of the spacious silica screen work of having out of basic structural unit with silicon (aluminum) oxygen tetrahedron, [SiO
4]
4-In Si be SP3 hydridization, be tetrahedral structure, silicon (aluminum) atom occupies tetrahedral center, four oxygen atoms are positioned at tetrahedral four drift angles. [Si-O] bond distance is 0.162 nm, and [O-O] bond distance is 0.264 nm.Because the character of aluminum is similar with silicon, aluminum atom instead silicon atom forms aluminum-oxygen tetrahedron [AIO
4]
5-, wherein [Al-O] bond distance is 0.175 nm, [O-O] bond distance is 0.286nm.Silicon-oxy tetrahedron interconnects through the oxygen atom that is in tetrahedron top, forms circulus tandem array, hollow, constitutes silicon (aluminum) oxygen tetrahedral group, becomes the skeleton of zeolite.The silicon of this spaciousness (aluminum) oxygen framing structure, bug hole, geode and duct with many marshallings make zeolite have stronger cation exchange property and absorption property.Have bigger specific surface area and inner highfield just because of zeolite, it has very strong adsorption to moisture isopolarity molecule, makes the wound platelet concentrate, moment intensive platelet, thereby wound is solidified.Research shows that also zeolite is met blood can discharge calcium ion, promotes platelet and fibrin to assemble, and shortens activated partial thromboplastin time.
The present invention is embodied in the existing tourniquet bandage as main material with zeolite; Because zeolite suction meeting heat release may cause wound further to be burnt, in order to reduce this calcination; The present invention also need add one or more in a certain amount of sodium chloride, potassium nitrate, ammonium salt, carbamide, the sodium bicarbonate; These materials can not only absorb zeolite because of the suction liberated heat, thereby reduce even avoid the burning sensation of human body wound, and some material also has antibacterial, disinfectant function.On the other hand, because zeolite is loose than Gypsum Fibrosum, adhesion strength is low, has also added a spot of binding agent among the present invention.
On hospital gauze, adsorb hemostatic compositions among the present invention, this hemostatic compositions is main constituent with the zeolite powder, can play the purpose of quick-acting haemostatic powder.Along with the increase of zeolite powder addition, its haemostatic effect is obvious more, but adds too much, and its heat release meeting is more remarkable, and therefore, for guaranteeing technique effect of the present invention, the present invention adopts 50% ~ 95% zeolite powder, 3% ~ 30% cooling agent, 2% ~ 20% binding agent.
The present invention is with coating on the hospital gauze oven dry, spool behind the hemostatic compositions mix homogeneously again, cut with aseptic sealed packages and form, and wherein the hemostatic compositions consumption is 20g at least on every square centimeter of hospital gauze.
As of the present invention preferred, said zeolite powder can pass through 20 ~ 230 purpose standard screens.Discover that through the inventor particle diameter of control zeolite powder is at 20 ~ 230 orders, the temperature that can control when can reach haemostatic effect in the water absorption course raises within the specific limits.
Add in sodium chloride, potassium nitrate, ammonium salt, carbamide, the sodium bicarbonate one or more among the present invention; These amount of substances bases wherein shape of content, granularity and these materials of zeolite powder are decided; The preferred ammonium chloride of above-mentioned ammonium salt, one or both in the ammonium nitrate.These materials can not only absorb because of zeolite suction emit the part heat, the control temperature is 40
oAbout C, thereby the wounded is not felt well or it is caused calcination, can also play antibacterial, thromboplastic effect.
As of the present invention preferred, said binding agent is one or more in sodium silicate, calcium chloride, calcium sulfate, montorillonite clay, Kaolin, the polyvinyl alcohol.
Directly tear packing when the present invention uses, wrapping gets final product on wound.
In sum, the present invention compared with prior art has following outstanding advantage and beneficial effect:
1, the present invention once forms hemostatic compositions and binder, sterile sealing, carry, preserve and use all convenient; Bleeding stopping period is less than 50 seconds, does not need to apply voluntarily, does not also destroy limb necrosis; Not only for the first-aid personnel provides effective means, and the wounded only otherwise lose consciousness and all can give treatment to voluntarily;
2, main material of the present invention source is abundant, and cost is low, and production technology is simple and haemostatic effect good, heat release is few, and hemostasis bacterial infection can not take place, for treatment and rescue have delayed the time;
3, the present invention is applied widely, is suitable for dangerous work post personnel and general workmens such as soldier, driver, work high above the ground, can be widely used as laboratory, the medical station, and the first-aid kit of family emergency and field work, market prospect is wide, has bigger economic benefit.
Survival rate and wound surface situation behind haemostatic effect of the present invention, wound surface local temperature, the hemostasis 5hr, referring to following experiment:
Select 9 of healthy rabbits, about body weight 2.5kg, be divided into three groups, after the anesthesia; Lying on the back is fixed on the laboratory table, with its right back femur ditch place QUMAO, peels off femoral artery, behind the blood ejection 4s; First group is used Zeolite hemostatic binder of the present invention, second group of Quikclot styptic powder of spilling purchase, and the 3rd group is sprayed YUNNAN BAIYAO, observes bleeding stopping period; The maximum temperature of hemostasis, and the hemostasis 5h after wound surface situation and survival rate, see table 1; The result finds that Zeolite hemostatic binder of the present invention (first group) bleeding stopping period is 50s ± 1s, and the maximum temperature that reaches is 42
oC, 3 all existence, Quikclot styptic powder (second group) bleeding stopping period is 65s ± 2s, the maximum temperature that reaches is 70
OC, 3 all existence, YUNNAN BAIYAO (the 3rd group) bleeding stopping period 180s ± 2s, maximum temperature 35
OC, 1 survival, 2 death, bleeding stopping period clearly of the present invention is short, and wound is not affected by the external environment; After opening binder, wound surface is sealed up, and heat release is few, and the Quikclot styptic powder is sprinkled upon on the wound, because inhomogeneous; Causing some place to be stopped blooding, is also bleeding in some place, and exothermic temperature is high, behind the hemostasis 5h; Wound surface is rubescent, possibly be the too high burn of bacterial infection or temperature, and behind the YUNNAN BAIYAO hemostasis 5h, wound surface is turned white.
Table 1
The specific embodiment
Below in conjunction with embodiment the present invention is done further explain.
Embodiment 1
A kind of Zeolite hemostatic binder; Coat on the hospital gauze again oven dry, spool behind the hemostatic compositions mix homogeneously of forming by 50% zeolite powder, 30% sodium chloride, 20% sodium silicate by weight percentage, cut with aseptic sealed packages and form; Wherein the hemostatic compositions consumption is 60g on every square centimeter of hospital gauze, and wherein zeolite powder can pass through 20 mesh standard sieves.
Embodiment 2
A kind of Zeolite hemostatic binder; Coat on the hospital gauze again oven dry, spool behind the hemostatic compositions mix homogeneously of forming by 95% zeolite powder, 3% ammonium chloride, 2% montorillonite clay by weight percentage, cut with aseptic sealed packages and form; Wherein the hemostatic compositions consumption is 20g on every square centimeter of hospital gauze, and wherein zeolite powder can pass through 130 mesh standard sieves.
Embodiment 3
A kind of Zeolite hemostatic binder; Coat on the hospital gauze again oven dry, spool behind the hemostatic compositions mix homogeneously of forming by 80% zeolite powder, 10% carbamide, 10% calcium chloride by weight percentage, cut with aseptic sealed packages and form; Wherein the hemostatic compositions consumption is 40g on every square centimeter of hospital gauze, and wherein zeolite powder can pass through 230 mesh standard sieves.
Embodiment 4
A kind of Zeolite hemostatic binder; Coat on the hospital gauze again oven dry, spool behind the hemostatic compositions mix homogeneously of forming by 85% zeolite powder, 2% potassium nitrate and 3% ammonium nitrate, 7% Kaolin and 3% calcium chloride by weight percentage, cut with aseptic sealed packages and form; Wherein the hemostatic compositions consumption is 30g on every square centimeter of hospital gauze, and wherein zeolite powder can pass through 100 mesh standard sieves.
Embodiment 5
A kind of Zeolite hemostatic binder; Coat on the hospital gauze again oven dry, spool behind the hemostatic compositions mix homogeneously of forming by 75% zeolite powder, 5% sodium chloride and 9% sodium bicarbonate, 6% sodium silicate and 5% calcium chloride by weight percentage, cut with aseptic sealed packages and form; Wherein the hemostatic compositions consumption is 50g on every square centimeter of hospital gauze, and wherein zeolite powder can pass through 120 mesh standard sieves.
This specific embodiment only is to explanation of the present invention; It is not the restriction to invention; Those skilled in the art can make any modification to present embodiment as required after reading this description, but as long as in claim scope of the present invention, all receive the protection of Patent Law.
Claims (5)
1. Zeolite hemostatic binder; Comprise hospital gauze; It is characterized in that: on hospital gauze, be adsorbed with hemostatic compositions, said hemostatic compositions comprise by weight percentage in 50% ~ 95% zeolite powder, 3% ~ 30% sodium chloride, potassium nitrate, ammonium salt, carbamide, the sodium bicarbonate one or more, 2% ~ 20% binding agent.
2. according to the said a kind of Zeolite hemostatic binder of claim 1; It is characterized in that: said Zeolite hemostatic binder is with coating on the hospital gauze oven dry, spool behind the hemostatic compositions mix homogeneously again, cut with aseptic sealed packages and form, and wherein the hemostatic compositions consumption is 20g at least on every square centimeter of hospital gauze.
3. according to the said a kind of Zeolite hemostatic binder of claim 2, it is characterized in that: said zeolite powder can pass through 20 ~ 230 purpose standard screens.
4. according to the said a kind of Zeolite hemostatic binder of claim 2, it is characterized in that: said binding agent is one or more in sodium silicate, calcium chloride, calcium sulfate, montorillonite clay, Kaolin, the polyvinyl alcohol.
5. according to the said a kind of Zeolite hemostatic binder of claim 1, it is characterized in that: said ammonium salt is an ammonium chloride, one or both in the ammonium nitrate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103116523A CN102366640A (en) | 2011-10-14 | 2011-10-14 | Zeolite tourniquet bandage |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103116523A CN102366640A (en) | 2011-10-14 | 2011-10-14 | Zeolite tourniquet bandage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102366640A true CN102366640A (en) | 2012-03-07 |
Family
ID=45759259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011103116523A Pending CN102366640A (en) | 2011-10-14 | 2011-10-14 | Zeolite tourniquet bandage |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102366640A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103041457A (en) * | 2012-11-07 | 2013-04-17 | 中国人民解放军第二军医大学 | Emergency tourniquet |
| CN108158731A (en) * | 2018-02-24 | 2018-06-15 | 中国人民解放军总医院 | Special technical soldier's first-aid dressing |
| CN111714683A (en) * | 2019-03-19 | 2020-09-29 | 广东博与再生医学有限公司 | Bone hemostatic material and preparation method thereof |
| CN112402684A (en) * | 2020-11-25 | 2021-02-26 | 联科华技术有限公司 | Monoatomic antibacterial disinfecting hemostatic gauze and preparation method thereof |
| CN112900095A (en) * | 2021-01-29 | 2021-06-04 | 明光市铭垚凹凸棒产业科技有限公司 | Composite gauze and preparation method and application thereof |
| CN113398319A (en) * | 2021-07-21 | 2021-09-17 | 军事科学院系统工程研究院卫勤保障技术研究所 | Preparation method of hemostatic material and product |
| CN118873717A (en) * | 2024-08-30 | 2024-11-01 | 浙江大学 | A zeolite-kaolin composite hemostatic gauze and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007128926A1 (en) * | 2006-05-10 | 2007-11-15 | Produits Dentaires Pierre Rolland | Paste for use as a bandage on mucous membranes of the oral cavity or on the skin |
| CN101104081A (en) * | 2006-07-14 | 2008-01-16 | 天津瀚康生物科技有限公司 | Flocculation method protein-removed natural emulsion self-adhesive elastic bandage and its manufacturing method |
| US20080097271A1 (en) * | 2006-10-20 | 2008-04-24 | Z-Medica Corporation | Devices and methods for the delivery of hemostatic agents to bleeding wounds |
| CN101342189A (en) * | 2008-08-28 | 2009-01-14 | 浙江大学 | Preparation method of emergency life-saving hemostatic agent with stamen complex for external use |
| US20090299253A1 (en) * | 2003-09-12 | 2009-12-03 | Hursey Francis X | Blood clotting compositions and wound dressings |
| CN102046123A (en) * | 2008-05-28 | 2011-05-04 | 尤妮佳股份有限公司 | Absorptive article and sanitary napkin |
-
2011
- 2011-10-14 CN CN2011103116523A patent/CN102366640A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090299253A1 (en) * | 2003-09-12 | 2009-12-03 | Hursey Francis X | Blood clotting compositions and wound dressings |
| WO2007128926A1 (en) * | 2006-05-10 | 2007-11-15 | Produits Dentaires Pierre Rolland | Paste for use as a bandage on mucous membranes of the oral cavity or on the skin |
| CN101104081A (en) * | 2006-07-14 | 2008-01-16 | 天津瀚康生物科技有限公司 | Flocculation method protein-removed natural emulsion self-adhesive elastic bandage and its manufacturing method |
| US20080097271A1 (en) * | 2006-10-20 | 2008-04-24 | Z-Medica Corporation | Devices and methods for the delivery of hemostatic agents to bleeding wounds |
| CN102046123A (en) * | 2008-05-28 | 2011-05-04 | 尤妮佳股份有限公司 | Absorptive article and sanitary napkin |
| CN101342189A (en) * | 2008-08-28 | 2009-01-14 | 浙江大学 | Preparation method of emergency life-saving hemostatic agent with stamen complex for external use |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103041457A (en) * | 2012-11-07 | 2013-04-17 | 中国人民解放军第二军医大学 | Emergency tourniquet |
| CN103041457B (en) * | 2012-11-07 | 2016-03-02 | 中国人民解放军第二军医大学 | A kind of emergency tourniquet |
| CN108158731A (en) * | 2018-02-24 | 2018-06-15 | 中国人民解放军总医院 | Special technical soldier's first-aid dressing |
| CN108158731B (en) * | 2018-02-24 | 2019-01-29 | 中国人民解放军总医院 | Special technical soldier's first-aid dressing |
| CN111714683A (en) * | 2019-03-19 | 2020-09-29 | 广东博与再生医学有限公司 | Bone hemostatic material and preparation method thereof |
| CN112402684A (en) * | 2020-11-25 | 2021-02-26 | 联科华技术有限公司 | Monoatomic antibacterial disinfecting hemostatic gauze and preparation method thereof |
| CN112900095A (en) * | 2021-01-29 | 2021-06-04 | 明光市铭垚凹凸棒产业科技有限公司 | Composite gauze and preparation method and application thereof |
| CN113398319A (en) * | 2021-07-21 | 2021-09-17 | 军事科学院系统工程研究院卫勤保障技术研究所 | Preparation method of hemostatic material and product |
| CN113398319B (en) * | 2021-07-21 | 2022-07-29 | 军事科学院系统工程研究院卫勤保障技术研究所 | Preparation method of hemostatic material and product |
| CN118873717A (en) * | 2024-08-30 | 2024-11-01 | 浙江大学 | A zeolite-kaolin composite hemostatic gauze and preparation method thereof |
| CN118873717B (en) * | 2024-08-30 | 2025-01-07 | 浙江大学 | Zeolite-kaolin composite hemostatic gauze and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102366640A (en) | Zeolite tourniquet bandage | |
| US20080319476A1 (en) | Hemostatic mineral compositions and uses thereof | |
| Dai et al. | Molecular imprinted macroporous chitosan coated mesoporous silica xerogels for hemorrhage control | |
| US8257731B2 (en) | Devices and methods for the delivery of molecular sieve materials for the formation of blood clots | |
| US9821084B2 (en) | Hemostasis of wound having high pressure blood flow using kaolin and bentonite | |
| KR102037150B1 (en) | Hemostatic devices | |
| US8252344B2 (en) | Partially hydrated hemostatic agent | |
| US9302025B2 (en) | Hemostatic compositions and methods of use | |
| EP1983951B1 (en) | Adsorbent-containing hemostatic devices | |
| US20080125686A1 (en) | Heat mitigating hemostatic agent | |
| US20080097271A1 (en) | Devices and methods for the delivery of hemostatic agents to bleeding wounds | |
| US20070104768A1 (en) | Devices for the delivery of molecular sieve materials for the formation of blood clots | |
| EP1810697A2 (en) | Devices for the delivery of molecular sieve materials for the formation of blood clots | |
| CN101104080A (en) | Zeolite hemostatic dressing and its preparation method and use | |
| WO2008034304A1 (en) | Nanometer mesoporous silica-based xerogel styptic material and its preparing process and application | |
| US20060141060A1 (en) | Molecular sieve materials having increased particle size for the formation of blood clots | |
| CN102133421A (en) | Rapidly-hemostatic wound dressing as well as preparation method and application thereof | |
| US20140220103A1 (en) | Hemostatic dressing for arterial bleeding | |
| US20060070523A1 (en) | Sodium permanganate ethylene absorption agent | |
| JPH026659A (en) | Fibrous absorbing body having enhanced deodorizing properties | |
| GB2466979A (en) | Porous ceramic compositions for use as haemostatic agents | |
| IL283596B1 (en) | Hemostatic composition and preparation method therefor | |
| TR201612824A1 (en) | A NEW TOPICAL HEMOSTATIC AGENT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120307 |